Results 21 to 30 of about 747,551 (253)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery [PDF]

, 2010
BACKGROUND: In newly diagnosed patients with Hodgkin lymphoma (HL) the effect of doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD)-related neutropenia on chemotherapy delivery is poorly documented.
Lyman, Gary H., Lyman, Gary H, Szucs Thomas D, Culakova Eva, Szucs, Thomas D., Thomas D Szucs, Pettengell, Ruth, Szucs, Thomas D, Eva Culakova, Lyman, GH, Culakova, Eva, Ruth Pettengell, Matthias Schwenkglenks, Pettengell, R, Schwenkglenks, Matthias, Szucs, TD, Gary H Lyman, Pettengell Ruth, Culakova, E, Schwenkglenks Matthias, Lyman Gary H, Lyman, G H, Szucs, T D, Schwenkglenks, M   +23 more
core   +1 more source

Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer

Cancer Medicine, 2018
To identify impacts of different combined regimens of stereotactic body radiation therapy (SBRT) and chemotherapy on survival of patients with locally advanced pancreatic cancer (LAPC) and factors correlated with determinations of different combinations.
Xiaofei Zhu, Dongchen Shi, Fuqi Li, Xiaoping Ju, Yangsen Cao, Yuxin Shen, Fei Cao, Shuiwang Qing, Fang Fang, Zhen Jia, Huojun Zhang   +10 more
doaj   +1 more source

Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy: Which is better in patients with radically resected extrahepatic biliary tract cancer?: a non-randomized, single center study

BMC Cancer, 2009
Background There is currently no standard adjuvant therapy for patients with curatively resected extrahepatic biliary tract cancer (EHBTC). The aim of this study was to analyze the clinical features and outcomes between patients undergoing adjuvant ...
Kim Tae-You, Im Seock-Ah, Jang Jin-Young, Chie Eui, Oh Do-Youn, Lim Kyu-Hyoung, Kim Sun-Whe, Ha Sung, Bang Yung-Jue   +8 more
doaj   +1 more source

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial [PDF]

, 2006
Oral capecitabine (Xeloda^®) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer.
F Coxon, T S Maughan, Douillard, J.Y., Lesniewski-Kmak, K, Bertetto, O., Jelic, S., Maughan, T.S., Dufour, A., J-Y Douillard, Johnston, P G, C Twelves, Díaz-Rubio, E., Cassidy, J, Twelves, C., Jelic, S, P G Johnston, Figer, A, G Fountzilas, W Scheithauer, Patel, K K, Malzyner, A, Fountzilas, G., K Lesniewski-Kmak, A Malzyner, Maughan, TS, Bustová, I, Cowell, W., Garrison, L.P., Twelves, C, Díaz-Rubio, E, O Bertetto, W Cowell, Beham, A, S Jelic, Maughan, Tim, Dufour, P, J J McKendrick, Scheithauer, W., Douillard, JY, Cowell, W, Lesniewski-Kmak, K., Garrison, L P, Bustová, I., Beham, A., Fountzilas, G, Johnston, PG, A Beham, Garrison, LP, K K Patel, Patel, KK, I Bustová, Cassidy, J., McKendrick, J.J., Bertetto, O, L P Garrison, Coxon, F., Patel, K.K., Douillard, J-Y, P Dufour, A Figer, Johnston, P.G., Scheithauer, W, Coxon, F, Maughan, T S, McKendrick, JJ, J Cassidy, E Díaz-Rubio, McKendrick, J J, Malzyner, A., Figer, A.   +69 more
core   +1 more source

Ifosfamide with regional hyperthermia in soft-tissue sarcomas [PDF]

, 2003
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival.
M. Schlemmer, Wendtner, Clemens-Martin, C.M. Wendtner, R.D. Issels, Schlemmer, M., Issels, Rolf-Dieter   +5 more
core   +1 more source

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma

Frontiers in Oncology, 2022
BackgroundAdjuvant chemotherapy has been shown to produce a favorable prognosis for patients with resectable mucosal melanoma (MM), resulting in the need for stratification to optimally select patients to benefit from adjuvant therapy.
Lirui Tang, Xiaoting Wei, Caili Li, Jie Dai, Xue Bai, Lili Mao, Zhihong Chi, Chuanliang Cui, Bin Lian, Bixia Tang, Yu Du, Xuan Wang, Yumei Lai, Xinan Sheng, Xieqiao Yan, Siming Li, Li Zhou, Yan Kong, Zhongwu Li, Lu Si, Jun Guo, Jun Guo   +21 more
doaj   +1 more source

Factors related to patient propensity to receive adjuvant chemotherapy and outcomes in stage III gastric cancer cases after D2 surgery

Asian Journal of Surgery, 2019
Summary: Background: Radical gastrectomy and extended lymph node (D2) dissection followed by adjuvant chemotherapy is the optimal treatment for patients with stage III gastric cancer in Asian population.
Jen-Shi Chen, Chia-Yen Hung, Keng-Hao Liu, Chun-Yi Tsai, Yung-Chia Kuo, Jun-Te Hsu, Wen-Chi Chou   +6 more
doaj   +1 more source

The efficacy of adjuvant chemotherapy for older adults with stage II/III gastric cancer: a retrospective cohort study

BMC Cancer, 2023
Background Adjuvant chemotherapy is recommended as the standard treatment for patients with stage II/III resected gastric cancer. However, it is unclear whether older patients also benefit from an adjuvant chemotherapy strategy.
Yu-Hsuan Shih, Hsin-Chen Lin, Po-Wei Liao, Cheng-Wei Chou, Cheng-Hsien Lin, Chiann-Yi Hsu, Chieh-Lin Jerry Teng, Feng-Hsu Wu, Shao-Ciao Luo, Shao-Hsuan Kao   +9 more
doaj   +1 more source

Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial

BMC Cancer, 2018
Background Some patients develop recurrence after curative resection and adjuvant chemotherapy. S-1, an oral fluoropyrimidine, is one of the standard regimens in adjuvant chemotherapy, and is also used in first-line treatment for advanced/metastatic ...
Seiji Ito, Yasuo Ohashi, Mitsuru Sasako
doaj   +1 more source

Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. [PDF]

, 2010
Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely
Clarkson, Jan E.; id_orcid, null The CSROC Expert Panel, Furness, Susan, Glenny, A.M., Oliver, R., Jan E Clarkson, Macluskey, Michaelina; id_orcid, Furness, S, Glenny, Anne-Marie, Macluskey, M., Clarkson, Jan E., The CSROC Expert Panel, CSROC Expert Panel, Chan, Kelvin K.W., Chan, K.K.W., Conway, DI, Clarkson, Jan E, Conway, David I., Glenny, AM, Clarkson, JE, Kelvin KW Chan, Pavitt, S., Worthington, Helen V, CSROC Expert Panel, [Unknown], Michaelina Macluskey, Furness, S., Worthington, Helen V., The CSROC Expert Panel,, Chan, Kelvin K. W., Pavitt, S, Chan, Kelvin KW, Anne-Marie Glenny, Oliver, R, Glenny, Anne Marie; id_orcid, David I Conway, Conway, D.I., Macluskey, Michaelina, Worthington, HV; id_orcid, Clarkson, J.E., Pavitt, Sue, Chan, KK, Worthington, HV, Macluskey, M, Worthington, Helen V.; id_orcid, Richard Oliver, Oliver, Richard, Helen V Worthington, Susan Furness, Sue Pavitt, Paul Brocklehurst, Worthington, H.V., Brocklehurst, Paul, Brocklehurst, P   +52 more
core   +1 more source